Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This page is an unofficial mirror and is not legal advice. Verify the document against the official source before relying on it.

HB1809: (New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Document type
Bill
Status
SENATE
Jurisdiction
NH
Branch
legislative
Citation
HB1809
Official source linked
Yes
Unofficial mirror
No
Extraction status
Unknown
OCR status
Unknown
Official source

Bill details

No mirrored bill text is available for this bill yet. Use the official source links below for the full current record.

Last sync warning: curl exited 52: curl: (52) Empty reply from server

Version history, amendments, and roll-call votes were not present in the imported local bill data.

Bill number
HB1809
Session year
2026
Status
SENATE
House status
PASSED/ADOPTED WITH AMENDMENT
Senate status
INEXPEDIENT TO LEGISLATE
Committee
Senate Health and Human Services
Hearing
04/08/2026 at 09:45 AM
Selected version
As Amended by the House
Last synced
2026-05-30T01:05:05.820Z

Official links

No mirrored full text is available for this record yet. Use the official source link above for the authoritative text.

Extraction diagnostics

Source fetched
no
Official source URL
yes
PDF mirrored
no
Text extracted
no

Related law links

RSA references from bill data

  • 126-Z · reference · effective 2030-11-01

    ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

  • 14:49 · reference · effective 2030-11-01

    disadvantages of the use of psilocybin for therapeutic purposes under this chapter and, if appropriate, design a program for the medical use of psilocybin. II. Notwithstanding RSA 14:49, the board shall consist of the following members: (a) The medical director of the department of health and human services, or designee. (b) A qualifying patient, appointed by the commissioner of the department of

RSAs mentioned by this document